You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CPD

ANCA-Associated Vasculitis: How Effective Is the Current Treatment Paradigm?

  • Authors: Neil Basu, MD, PhD; Joanna C. Robson, MD, PhD, FRCP; David Jayne, MD, FMedSci; Y.K.O. Teng, MD, PhD
  • CPD Released: 3/22/2021
  • THIS ACTIVITY HAS EXPIRED FOR CREDIT
  • Valid for credit through: 3/22/2022, 11:59 PM EST
Start Activity


Target Audience and Goal Statement

This educational activity is intended for an international audience of non-US nephrologists, rheumatologists, and primary care physicians.

The goal of this activity is to increase knowledge about current treatment options and their limitations, guideline recommendations, and recent clinical trial data for emerging therapies for patients with antineutrophil cytoplasmic antibody-associated vasculitis (AAV).

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Results from clinical trials that have compared the efficacy of immunosuppressive therapies used for remission-induction in patients with AAV
    • Efficacy and safety of the C5a-targeted therapies in patients with AAV
    • Guideline-based selection of the optimal duration of remission-maintenance therapy in patients with AAV


Disclosures

WebMD Global requires each individual who is in a position to control the content of one of its educational activities to disclose any relevant financial relationships occurring within the past 12 months that could create a conflict of interest.


Faculty

  • Neil Basu, MD, PhD

    Clinical Senior Lecturer in Rheumatology
    Honorary Consultant (Immunology)
    Associate, Institute of Neuroscience & Psychology
    University of Glasgow
    Glasgow, United Kingdom

    Disclosures

    Disclosure: Neil Basu, MD, PhD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Gilead; GlaxoSmithKline; Lilly; Merck Sharp & Dohme, Corp.
    Served as a speaker or a member of a speakers bureau for: AbbVie; Lilly; Roche; Vifor
    Received grants for clinical research from: GlaxoSmithKline; Lilly; Pfizer; Vifor; Vorso

  • Joanna C Robson, MD, PhD, FRCP

    Consultant Senior Lecturer in Rheumatology
    Centre for Health and Clinical Research
    University of the West of England, Bristol
    Consultant Rheumatologist
    University Hospitals Bristol and Weston NHS Foundation Trust
    Bristol, United Kingdom

    Disclosures

    Disclosure: Joanna C. Robson, MD, PhD, FRCP, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Vifor
    Received grants for clinical research from: Vifor

  • David Jayne, MD, FMedSci

    Professor of Clinical Autoimmunity
    University of Cambridge
    Cambridge, United Kingdom

    Disclosures

    Disclosure: David Jayne, MD, FMedSci, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: AstraZeneca; Aurinia; Bristol Myers Squibb Company; Boehringer Ingelheim; Chemocentryx; Chugai; CSL Behring; Genentech; GlaxoSmithKline; Infla-RX; Janssen; Novartis; Roche; Takeda; Vifor
    Received grants for clinical research from: GlaxoSmithKline
    Owns stock, stock options, or bonds from: Aurinia

  • Y.K.O. Teng, MD, PhD

    Department of Internal Medicine, Nephrology
    Expert Center for Lupus -- Vasculitis- and Complement-Mediated
    Systemic Autoimmune Diseases
    Leiden University Medical Center
    Leiden, the Netherlands

    Disclosures

    Disclosure: Y.K.O Teng, MD, PhD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Aurinia; GlaxoSmithKline; Novartis; Vifor
    Received grants for clinical research from: Aurinia; GlaxoSmithKline; Vifor

Editors

  • George Boutsalis, PhD

    Senior Medical Education Director, Medscape, LLC 

    Disclosures

    Disclosure: George Boutsalis, PhD, has disclosed no relevant financial relationships.  

  • Asha P. Gupta, PharmD, RPh

    Senior Scientific Content Manager, Medscape, LLC

    Disclosures

    Disclosure: Asha P. Gupta, PharmD, RPh, has disclosed no relevant financial relationships.

Content Reviewer

  • Robert Morris, PharmD

    Associate Director, Accreditation and Compliance

    Disclosures

    Disclosure: Robert Morris, PharmD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: ViiV Healthcare
    Owns stock, stock options, or bonds from: GlaxoSmithKline

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.


Accreditation Statements

    For Physicians

  • The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 0.75 continuing professional development credits (CPD).

    Contact WebMD Global

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information about your eligibility to claim credit, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent participating in the activity. To successfully earn credit, participants must complete the activity online during the credit eligibility period that is noted on the title page.

Follow these steps to claim a credit certificate for completing this activity:

  1. Read the information provided on the title page regarding the target audience, learning objectives, and author disclosures, read and study the activity content and then complete the post-test questions. If you earn a passing score on the post-test and we have determined based on your registration profile that you may be eligible to claim CPD credit for completing this activity, we will issue you a CPD credit certificate.
  2. Once your CPD credit certificate has been issued, you may view and print the certificate from your CME/CE Tracker. CPD credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of the Medscape Education homepage.

We encourage you to complete an Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.

CPD

ANCA-Associated Vasculitis: How Effective Is the Current Treatment Paradigm?

Authors: Neil Basu, MD, PhD; Joanna C. Robson, MD, PhD, FRCP; David Jayne, MD, FMedSci; Y.K.O. Teng, MD, PhDFaculty and Disclosures
THIS ACTIVITY HAS EXPIRED FOR CREDIT

CPD Released: 3/22/2021

Valid for credit through: 3/22/2022, 11:59 PM EST

processing....

Contents of This CPD Activity

All sections of this activity are required for credit.

Current Treatment Landscape for AAV


Neil Basu, MD, PhD

Challenges and Limitations of Current Treatment Practices


Joanna C. Robson, MD, PhD, FRCP

Guideline Recommendations for the Treatment of AAV


David Jayne, MD, FMedSci

Emerging Therapies in Development for AAV


Y.K.O. Teng, MD, PhD
 

Educational Impact Challenge

The goal of this activity is to increase knowledge about current treatment options and their limitations, guideline recommendations, and recent clinical trial data for emerging therapies for patients with antineutrophil cytoplasmic antibody-associated vasculitis (AAV).

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

  • Print